Celldex Therapeutics (CLDX) Operating Income (2016 - 2025)
Historic Operating Income for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$73.6 million.
- Celldex Therapeutics' Operating Income fell 4122.89% to -$73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.2 million, marking a year-over-year decrease of 3726.31%. This contributed to the annual value of -$195.1 million for FY2024, which is 2622.98% down from last year.
- Per Celldex Therapeutics' latest filing, its Operating Income stood at -$73.6 million for Q3 2025, which was down 4122.89% from -$63.9 million recorded in Q2 2025.
- In the past 5 years, Celldex Therapeutics' Operating Income ranged from a high of -$13.4 million in Q2 2021 and a low of -$73.6 million during Q3 2025
- For the 5-year period, Celldex Therapeutics' Operating Income averaged around -$38.8 million, with its median value being -$36.4 million (2022).
- As far as peak fluctuations go, Celldex Therapeutics' Operating Income surged by 1792.1% in 2021, and later plummeted by 17080.36% in 2022.
- Quarter analysis of 5 years shows Celldex Therapeutics' Operating Income stood at -$20.3 million in 2021, then tumbled by 37.09% to -$27.9 million in 2022, then crashed by 70.8% to -$47.6 million in 2023, then dropped by 17.64% to -$56.0 million in 2024, then tumbled by 31.4% to -$73.6 million in 2025.
- Its last three reported values are -$73.6 million in Q3 2025, -$63.9 million for Q2 2025, and -$62.7 million during Q1 2025.